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INTRODUCTION:  Male  breast  cancer  (MBC)  is a rare  disease  that  accounts  for <1%  of breast cancer  cases.  The
most  common  treatment  is  modiﬁed  radical  mastectomy  (MRM).  Recently,  breast  conservative  surgery
(BCS)  is getting  popular  for MBC  treatment.  We  report  a case  and  reviewed  the  literature  to investigate
whether  emerging  BCS  can  be  considered  as an alternative  of  a more  radical  surgery.
PRESENTATION  OF  CASE:  A 46  y.o.  patient,  presented  with  a painless  left breast  lump  over  a  period  of six
months. The  patient  underwent  a  quadrantectomy  at another  institution.  Pathology  revealed  an  intraduc-
tal  carcinoma  in close  proximity  to  the  margins  of  excision.  Adjuvant  hormonal  therapy  was  proposed
to  the  patient,  who  refused  and  was  referred  to our  Institution.  We  performed  a MRM  and  a  sentinel
lymph  node  biopsy  (SLNB).  A  contralateral  breast  liposuction  and  an  adenectomy  were  also  performed.
The  patient  underwent  also  a nipple-areolar  complex  reconstruction.  The patient  didn’t  receive  adjuvant
therapy.
DISCUSSION:  Both  oncological  safety  and  satisfactory  cosmetic  outcomes  are  the  goals  of  MBC  treatment.
No  speciﬁc  guidelines  for  MBC  treatment  have  been  proposed.  MRM is  currently  the surgical  gold  stan-
dard of MBC  (approximately  70%  of  all  cases).  Some  authors  reported  that  male  BCS associated  with
radiation  therapy  is a  feasible  alternative  MRM.  Taking  into  account  data  from  the  literature  and  con-
sidering  the previous  surgery,  in  the  case  we  report,  we  offered  a MRM,  SLNB  and  a contralateral  breast
symmetrization.
CONCLUSION:  MRM  with  SLNB  and  reconstruction  of  male  breast  asymmetry  should  be  still  considered
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. Introduction
Male breast cancer (MBC) is a rare disease that accounts for < 1%
f all breast cancer cases and < 1% of all male cancers [1]. However,
s female breast cancer (FBC), the incidence of MBC  has increased
ver the past 25 years [2]. The median age at diagnosis of breast
ancer is slightly older in men  (67 y.o.) than in females (62 y.o.) [3].
he typical presentation of breast cancer onset in men  is a unilateral
ainless palpable mass in a central sub-areolar location or eccen-
ric to the nipple-areolar complex with early nipple involvement
4,5]. According to literature data, most of male breast cancers are
nvasive ductal carcinoma (85–90%) [4,6]. About 65–90% of MBC
re estrogen and progesterone receptor positive, similarly to (FBC)
reast cancer in menopausal women [7]. MBC  causes a higher mor-
ality than the female counterpart [6]. MBC  patients have a worse
urvival rate compared to women, because of a more advanced dis-
ase and an older age at diagnosis [2,4]. According to the literature
n the treatment of MBC, modiﬁed radical mastectomy is generally
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210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
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preferred to breast conservation surgery (BCS) [8,9]. Some others
reported more radical surgical approach; 71% of patients in San-
guinetti paper treated with more radical treatment such as radical
mastectomy (RM) [10].
However, as for FBC treatment, minimally invasive surgical pro-
cedures are getting increasingly popular for MBC  treatment [8,11].
According to Zaenger study, in the preliminary data collected from
the European Organization for Research and Treatment of Cancer
(EORTC) 56% of MBC  patients had stage T1 cancer, but only 4% had
undergone breast conservation surgery [12]. We  report a case of
MBC  treatment and we  extensively reviewed pertinent literature of
the last 10 years to investigate whether BCS can be considered as the
gold standard treatment, or if a more radical surgery is preferable.
2. Presentation of case
A 46 y.o. caucasian patient, amateur swimmer, with no signif-
icant past medical history and no family history of breast cancer,
presented with a painless left breast lump and nipple bloody dis-
charge over a period of six months. Physical examination revealed
a ﬁrm mass in the Upper Outer Quadrant (UOQ). Mammogra-
phy and breast ultrasonography conﬁrmed the presence of the
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Multistage surgical management of MBC. (a) Post conservative surgery appearance of the patient. (b) Four months after mastectomy and before NAC reconstruction.
(c)  Six months postoperative result.
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iFig. 2. (a) Left modiﬁed radical mastectomy: the breast tissue is de
eoplastic mass. No pathological lymph nodes were detected in
he axilla at the clinical and ultrasound examination. Furthermore
he patient shows a I grade gynecomastia [13]. The patient under-
ent a nipple sparing upper outer quadrantectomy with excision
f the retro-areolar tissue to the left breast at another institu-
ion. (Fig. 1) Pathology revealed a low-grade intraductal carcinoma,
linging and micropapillary type, ER/PR+. The tumor was  in close
roximity to the margins of excision. The cancer TNM staging was
A (pT1,N0,MO) according to AJCC guidelines [14]. Adjuvant hor-
onal therapy was proposed to the patient. He refused a prolonged
ndocrine therapy and was  referred to our Institution for an onco-
ogical and surgical advice.
On the basis of the pathology report and the relative residual
aucity of breast tissue, we proposed to the patient a modiﬁed
adical mastectomy as an alternative to adjuvant hormonal ther-
py. The patient accepted the suggested surgical treatment. A
eft modiﬁed radical mastectomy and sentinel lymph node biopsy
ere performed, and associated with a contralateral breast lipo-
uction and adenectomy, as indicated in a grade II gynecomastia
13] (Fig. 2). Four months later the patient underwent a left
ipple-Areolar complex (NAC) reconstruction under local anesthe-
ia. Areolar reconstruction was performed using a full-thickness
kin graft from the ipsilateral groin, while nipple reconstruction
as achieved using a subdermal single pedicle local ﬂap (Fig. 3).
istologic examination of the residual breast parenchyma revealed
he persistence of sparse foci of intra-ductal carcinoma, clinging
nd micropapillary type, with tumor free margins, while the SLNB
as negative for metastatic disease. Histological examination of
ontralateral breast was also negative. The patient did not receive
ny adjuvant therapy. He is currently under oncological follow-up
ccording to the International guidelines established for FBC, and
s free from at 18 months follow-up [14].d from the pectoralis major muscle. (b) Sample of the mastectomy.
3. Discussion
National Comprehensive Cancer Network (NCCN) guidelines for
FBC treatment and surveillance are well established, but no speciﬁc
guidelines for male patients exists, and no clinical trials or prospec-
tive studies have been performed. In the absence of deﬁnite data,
the treatment of MBC  has traditionally followed guidelines estab-
lished for FBC [1,15–18]. However, modiﬁed radical mastectomy
is currently the surgical gold standard treatment of MBC  (approxi-
mately 70% of all cases), followed by radical mastectomy (8–30%),
total mastectomy (5–14%), and lumpectomy with or without irradi-
ation (1–13%) [2,19]. According to the Surveillance, Epidemiology
and End Results (SEER) program, between 1983 and 2009, 4707
(86.8%) MBC  patients underwent mastectomy while 718 (13.2%)
underwent breast conservation surgery (i.e., lumpectomy) [16,18].
Although breast conservation surgery (BCS) has not known the
same widespread acceptance as in FBC patients, BCS is getting
popular also for MBC  treatment [11]. Nowadays, lumpectomy is
performed in a small but rising proportion of MBC  patients; as
reported by the SEER database, the rate of patients undergoing
lumpectomy between 2007 and 2009 is signiﬁcantly superior to the
corresponding rate between 1983 and 1986 (15.1% vs. 10.6%). Some
authors reported that breast conservation surgery associated with
radiation therapy, in selected patients, is a feasible alternative to
total or modiﬁed radical mastectomies [8,11,16,21]. The literature
review showed that male patients reported to have conservative
surgery were likely to be of black race and elderly; they did not
receive lymph node sampling, had advanced stage disease, and
were often treated with palliative purposes [1,4,8].Conservative surgery has the disadvantage of requiring adju-
vant radiation therapy and, in selected patients, hormonal therapy
to reach the same safety of mastectomy. Radiation therapy involves
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[5] T.J. Tan, L.C. Leong, L.S. Sim, Clinics in diagnostic imaging (147). Male breastFig. 3. Nipple-Areolar complex (NAC) reconstruction. Intraoperative view.
uite a few sequelae and men  are usually more reluctant than
omen to receive it [1]. According to the SEER data, just the 35%
f patients treated with lumpectomy also received radiation ther-
py, while the others (75%) received surgery alone [16,18]. This
ata reveal that men  undergoing breast conservation surgery may
eceive a suboptimal treatment, not safe as mastectomy and with
 higher recurrence rate. Physical and emotive consequences of
ormonal therapies and chemotherapies, including the fear for an
masculating therapy and sexual dysfunction, are more problem-
tic than in the female counterpart, which limits their indications
n male patients. As said by the recent literature [8,11,12,16,17]
merging BCS, in early stage MBC, has comparable survival rates to
RM and has been progressively more performed in the last years.
espite the current transition from radical to conservative surgical
reatment of MBC, we retain that MRM  is still regarded as the stan-
ard treatment due to the paucity of male breast tissue, the typical
entral sub-areolar location of the cancer with early nipple involve-
ent and the debilitating side effects of adjuvant therapy necessary
n BCS. Moreover scarring and chest wall deformity resulting from
he male mastectomy are less disﬁguring than in female patients.
aking into account literature data and considering tumor histol-
gy and the pathologic close margins of the previous surgery, in
he case we report, we  offered a modiﬁed radical mastectomy and
entinel lymph node biopsy. The patient agreed with the proposed
reatment, preferring to receive a radical surgery, rather than an
djuvant treatment [20].
Also, we decided for a comprehensive cosmetic treatment and
eshaping of the entire chest wall, achieved through NAC recon-
truction and contralateral symmetrization (Fig. 1).
MBC  involves patients between the ﬁfth and sixth decades of life,
hen a moderate grade of gynecomastia is physiological [17]. In our
atient the breast symmetry was achieved performing a contralat-
ral liposuction and adenectomy instead of the volume replacing of
he mastectomy side [6]. This approach let to perform a prophylac-
ic adenectomy in patients with an additional risk of contralateralPEN  ACCESS
rgery Case Reports 30 (2017) 89–92 91
cancer. The contralateral breast treatment has both oncological and
aesthetic purposes.
The patient was satisﬁed with the cosmetic outcome and went
back to his recreational activities, starting again to swim, with no
shame or concern to show his chest. Men  who undergo mastec-
tomies usually complain unsatisfactory aesthetic results because of
the excision of the NAC and the alteration of the normal male chest
contour [21]. Thus, post-oncological male chest reshaping should
be regularly considered in men, in order to reduce postoperative
psychological distress by restoring the patient’s body image.
4. Conclusion
Male breast cancer should be treated as a rare and unique dis-
ease, rather than just as a hormone-positive cancer that mainly
affects postmenopausal women  [1,9] Based on the physical and
psychological factors related to the male sex as well as on oncolog-
ical considerations, we believe that modiﬁed radical mastectomy
with sentinel lymph node biopsy (SLNB) or axillary dissection and
reconstruction of male breast asymmetry should be considered as
the treatment of choice of MBC, as this radical and comprehensive
treatment guarantees both an optimal oncologic care and cosmetic
result.
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